（编辑 李家琪 张昕） 本报讯 （记者李雯珊 见习记者张美娜）10月21日，国药集团一致药业股份有限公司（以下简称"国药一致"）披露的2025 年前三季度业绩快报显示，公司实现营业总收入约为551.24亿元，同比下降2.38%；归母净利润约为9.57亿元，同比下降 10.18%。根据公告，公司将继续聚焦"开源、节流、提效"，加速数字化转型，深化组织变革与精细化管理，调整业务结构，提 升经营质量与抗风险能力。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：002727 股票简称：一心堂 公告编号：2025-096号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会，审议通过 《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使用额度不超过人民 币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型 理财产品、大额存单、定期存款、通知存款、协定存款等），相关额度在投资期限内任一时点的现金管 理金额(含前述投资的收益进行再投资的相关金额)不超过25亿元人民币。在上述额度内，资金可以滚动 使用，在额度范围内授权董事长具体办理实施相关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司分别与华夏银行股份有限公司昆明红塔支行及广发银行股份有限公司昆明万宏支行签订了 《华夏银行人民币单位结构性 ...

智通财经APP讯，国药控股(01099)公布附属国药股份(600511.SH)2025年前三季度业绩，公司前三季度 实现营收393.81亿元，同比增长3.56%;归属于上市公司股东的净利润14.92亿元，同比增长0.74%;扣非净 利润14.7亿元，同比下降1.27%;基本每股收益1.9778元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立之股份有限公司 , 在香港以國控股份有限公司之名稱經營業務 ) (股份代號 :01099) 海外監管公告 國藥集團藥業股份有限公司 2025 年第三季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列國藥控股股份有限公司旗下一間 A 股於上海證券交易所上市的附屬公司，國 藥集團藥業股份有限公司,於 2025 年 10 月 21 日於上海證券交易所網站刊發的《國藥 集團藥業股份有限公司 2025 年第三季度報告》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先 生、祖敬先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李 培育先生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinoph ...

Core Insights - The company reported a total operating revenue of approximately 55.12 billion yuan for the first three quarters of 2025, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was approximately 957 million yuan, down 10.18% year-on-year [1] - The basic earnings per share were 1.72 yuan [1] Distribution Segment - The distribution segment achieved operating revenue of 40.59 billion yuan from January to September 2025, a year-on-year decline of 0.59% [2] - Net profit for the distribution segment was 723 million yuan, down 7.32% year-on-year [2] - Despite ongoing policy and market competition pressures, the company managed to stabilize distribution revenue through continuous optimization of its business structure [2] Retail Segment - The retail segment, represented by "Guoyao Holdings Guoda Pharmacy Co., Ltd.", generated operating revenue of 15.23 billion yuan, a year-on-year decrease of 7.14% [2] - The net profit for the retail segment was 13 million yuan, showing a significant year-on-year increase of 133.91% [2] - The retail segment faced challenges from the market environment and strategic store closures, but improved profitability through optimization of procurement systems and closure of inefficient stores [2]

Core Insights - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for the first nine months of 2025, indicating challenges in the pharmaceutical sector [1] Financial Performance - For the period of January to September 2025, China National Pharmaceutical Group's subsidiary, China National Pharmaceutical (国药一致), achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders of China National Pharmaceutical was 0.957 billion yuan, reflecting a year-on-year decline of 10.18% [1] - Basic earnings per share decreased by 9.95%, and the weighted average return on net assets fell by 0.70 percentage points year-on-year [1] Quarterly Results - In the third quarter of 2025, China National Pharmaceutical reported a revenue of 18.328 billion yuan, down 1.89% compared to the same period last year [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, showing a year-on-year decline of 9.58% [1]

Core Insights - The company reported a net profit increase of 13.10% year-on-year for the third quarter of 2025 [1] - The total revenue for the third quarter reached 13.747 billion yuan, reflecting a year-on-year growth of 3.58% [1] Financial Performance - The company's revenue for Q3 2025 was 13.747 billion yuan, which is an increase of 3.58% compared to the same period last year [1] - The net profit attributable to shareholders was 544 million yuan, showing a growth of 13.10% year-on-year [1]

Core Insights - The company reported third-quarter revenue of 13.747 billion, representing a year-on-year increase of 3.58% [1] - Net profit for the third quarter was 544 million, showing a year-on-year growth of 13.10% [1] - For the first three quarters, total revenue reached 39.381 billion, with a year-on-year growth of 3.56% [1] - Net profit for the first three quarters was 1.492 billion, reflecting a year-on-year increase of 0.74% [1]

Core Viewpoint - China National Pharmaceutical Group Corporation (国药股份) reported a revenue of 39.381 billion yuan for the first three quarters, reflecting a year-on-year growth of 3.56% [1] - The net profit attributable to shareholders reached 1.492 billion yuan, showing a slight increase of 0.74% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 1.47 billion yuan, indicating a year-on-year decline of 1.27% [1] - Basic earnings per share stood at 1.9778 yuan [1] Financial Performance - Revenue for the first three quarters: 39.381 billion yuan, up 3.56% year-on-year [1] - Net profit attributable to shareholders: 1.492 billion yuan, up 0.74% year-on-year [1] - Net profit after deducting non-recurring items: 1.47 billion yuan, down 1.27% year-on-year [1] - Basic earnings per share: 1.9778 yuan [1]

Core Insights - The core viewpoint of the article highlights the financial performance of Jianmin Group for the third quarter of 2025, indicating a decline in both revenue and net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company's operating revenue was 747 million yuan, a year-on-year decrease of 14.27% [1] - The net profit for Q3 2025 was 65.11 million yuan, down 20.84% year-on-year [1] - For the first three quarters of 2025, the total operating revenue reached 2.552 billion yuan, reflecting an 11.43% decline compared to the same period last year [1] - The net profit for the first three quarters was 286 million yuan, which is an 11.16% decrease year-on-year [1] - The basic earnings per share stood at 1.88 yuan [1] Segment Performance - The pharmaceutical manufacturing segment experienced a year-on-year growth of 19.67%, attributed to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue, down 36.91%, due to the company's ongoing optimization of its commercial subsidiaries' business structure, leading to a reduction in low-margin and inefficient operations [1]